At corion biotech s.r.l. we are committed to develop innovative therapeutic solutions for Women’s health.

Our technology is based on a specific cell population derived from the human term placenta known as Placental Mesenchymal Stromal Cells (hPDMSCs).

By our property technology, we exploit the unique PDMSCs’s therapeutic abilities in-vitro to develop our “Cell Therapy without Cells”.

A cell therapy based on PDMSCs-derived biological cocktails instead of a direct administration of living cells to the patient is a totally new approach which maintains the effectiveness of cell therapy avoiding the risk of direct administration of living allogenic cells.

We strongly believe that our approach is the most ethical, safe and effective solution present in the Advanced Therapy Medicinal Products panorama.


Preeclampsia affects 3-8% of all pregnancies worldwide, thus being the main cause of fetal-maternal mortality and morbidity worldwide.

A new drug for Preeclampsia represent both an important improvement for the health of millions of mothers and children and a substantial saving for sanitary systems in developed countries.


Epithelial cancers affecting ovarian and breast tissues represent the first cause of death among all gynecological cancers.
Corion Biotech approach for epithelial gynecological cancers is based on hPDMSCs purified from the human preeclamptic placenta obtained immediately after delivery, expanded and cultured in vitro in order to naturally obtain our therapeutic biological CB-ChMF-12.

About us

Corion Biotech S.r.l. is an innovative startup founded in December 2012 as an Academic spin-off of the University of Turin


Our team as a record of more than 300 publications in international indexed medical-scientific journals in the field of Obstetrics & Gynaecology.

Drop us a line

Go to Top